To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
The development, manufacture and marketing of innovative in vitro diagnostics and medical devices with the aim of avoiding or alleviating the human papillomavirus (HPV) caused cancer diseases is our mission. Our core competency is in the use of immunological active components, such as a wide range of unique antibodies against different HP viruses and specific antigens. In Germany was the market launch of our first product the Prevo-Check® quick test in the early 2015 This in vitro diagnostic tool and represents the world's first commercially available method for specific screening of HPV-associated oral cavity carcinomas. Abviris Deutschland GmbH was founded in March 2014 by Dr. Ralf Hilfrich. The German market was in Frankfurt/Main the starting point of the company.
Prevo-Check® the rapid test for the early detection of HPV-related cancer precursors and tumors
The number of new cases of squamous cell carcinoma caused by HPV is rising rapidly. Significant differences in the localisation of cancerous lesions can be identified on a gender-specific basis. While women are predominantly affected by anogenital carcinomas, men are primarily affected by HPV-related head and neck tumors. In the United States and other developed countries, oral and pharyngeal carcinomas are now the most common type of HPV-related tumor. The early detection of these tumors is essential for a good prognosis. While no meaningful and practicable serological method for the early detection of HPV-caused tumors has been available to date, the new immunological rapid test Prevo-Check® is now available. The Prevo-Check® is an in-vitro diagnostic agent and represents the world's first commercially available method for the detection of HPV-associated squamous cell carcinoma of the anogenital region and in the mouth and throat. The test owes its exceptionally good performance data to the use of the special anti-HPV16 L1 DRH1 antibody clone, which is directed against a protein that is only produced by cells in which HPV16 has already actively intervened in cell division. This means that this antibody only occurs when a subclinical HPV16 infection has progressed to a precancerous stage or a carcinoma... The Prevo-Check® is exceptionally easy to perform and can be used both in practice and in the laboratory. The test kits contain all required materials; a device-based evaluation is not required. A single drop of blood is required to perform the Prevo-Check® rapid test; the result of the test is available within a few minutes.
- Rapid tests
- Test kits